化合物 MCC950|T3701|TargetMol

MCC950
210826-40-7

￥292 2mg 起订

￥427 5mg 起订

￥677 10mg 起订

上海更新日期：2025-11-17

TargetMol中国（陶术生物）

VIP4年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 化合物 MCC950

英文名称：: MCC950

CAS号：: 210826-40-7

品牌：: TargetMol

产地：: 美国

保存条件：: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

纯度规格：: 98.30%

产品类别：: 抑制剂

货号：: T3701

Product Introduction

Bioactivity

名称	MCC950
描述	MCC950 (CP-456773) is a NLRP3 inflammasome inhibitor (IC50=7.5-8.1 nM). MCC950 can be used to treat inflammatory diseases, inflammation-related tumors and neurodegenerative diseases.
细胞实验	MCC950 is dissolved in DMSO and stored, and then diluted with appropriate media before use[1]. BMDM are seeded at 5×105/mL or 1×106/mL, HMDM at 5×105/mL and PBMC at 2×106/mL or 5×106/mL in 96 well plates. The following day the overnight medium is replaced and cells are stimulated with 10 ng/mL LPS from Escherichia coli serotype EH100 (ra) TLRgrad for 3 h. Medium is removed and replaced with serum free medium (SFM) containing DMSO (1:1,000), MCC950 (0.001-10 μM), glyburide (200 μM), Parthenolide (10 μM) or Bayer cysteinyl leukotriene receptor antagonist 1-(5-carboxy-2{3-[4-(3-cyclohexylpropoxy)phenyl]propoxy}benzoyl)piperidine-4-carboxylic acid (40 μM) for 30 min. Cells are then stimulated with inflammasome activators: 5 mM adenosine 5'-triphosphate disodium salt hydrate (ATP) (1 h), 1 μg/mL Poly(deoxyadenylic-thymidylic) acid sodium salt (Poly dA:dT) transfected with Lipofectamine 200 (3-4 h), 200 μg/mL MSU (overnight) and 10 μM nigericin (1 h) or S. typhimurium UK-1 strain. Cells are also stimulated with 25 μg/mL Polyadenylic-polyuridylic acid (4 h). For non-canonical inflammasome activation cells are primed with 100 ng/mL Pam3CSK4 for 4 h, medium is removed and replaced with SFM containing DMSO or MCC950 and 2 μg/mL LPS is transfected using 0.25% FuGENE for 16 h. Supernatants are removed and analysed using ELISA kits. LDH release is measured using the CytoTox96 non-radioactive cytotoxicity assay[1].
激酶实验	Disk diffusion is conducted, except that 10 μg of each antibiotic compound is used per filter. Growth in liquid medium in the presence of CHIR-090 is evaluated as follows: cells from overnight cultures are inoculated into 50 mL portions of LB broth at an A600 of 0.02 and grown with shaking at 30°C. When the A600 reaches 0.15, parallel cultures are treated with either 6 μL of 500 μg/mL CHIR-090 in DMSO or 6 μL of DMSO. To assess cumulative growth, cultures are maintained in log phase growth by 10-fold dilution into pre-warmed medium, containing the same concentrations of DMSO or DMSO/CHIR-090, whenever the A600 reaches 0.4. The minimal inhibitory concentration is defined as the lowest antibiotic concentration at which no measurable bacterial growth is observed in LB medium containing 1% DMSO (v/v), when inoculated at a starting density of A600=0.01. Cultures are incubated with shaking for 24 h at 30°C in the presence of CHIR-090. Experiments are performed in triplicate[1].
体外活性	方法：HEK293细胞、HepG2细胞用MCC950处理后使用resazurin based fluorescence assay检测细胞毒性。结果：MCC950对HEK293细胞（CC50> 62.5 μM）、HepG2细胞（CC50> 62.5 μM）无毒。[1] 方法：人THP-1细胞用MCC950处理72小时后使用CCK-8方法检测细胞毒性。结果：MCC950抑制THP-1细胞生长（CC50=81.35 μM）。[2] 方法：人THP-1细胞用MCC950处理72小时后使用MTT方法检测细胞毒性。结果：MCC950抑制THP-1细胞生长（IC50=98.83 μM）。[3]
体内活性	方法：为研究MCC950的抗炎作用，将小鼠预先用MCC950处理1小时，然后腹腔注射LPS。结果：2小时后检测发现，MCC950可降低血清中IL-1β和IL-6的浓度，但对TNF-α的量影响不大，表明MCC950在体内具有活性。[4] 方法：为研究MCC950的抗炎作用，使用7周大的Winnie小鼠（Muc2基因突变，C57BL/6J背景），分为MCC950治疗组和对照组，每组10只。治疗组小鼠每天喂食含有40mg/kg MCC950的新鲜饲料糊，对照组喂食不含MCC950的饲料糊，实验持续21天。结果：MCC950治疗组小鼠的DAI评分显著降低，表明其粪便稠度和粪便中血液情况得到改善。治疗组小鼠的结肠长度增加，结肠重量减轻，说明结肠炎症减轻。H&E染色结果显示，MCC950治疗组小鼠的结肠炎症特征明显改善。[5] 方法：为研究MCC950对非肥胖糖尿病的影响，将MCC950腹腔注射给11周龄的雌性非肥胖糖尿病（NOD）小鼠，每周3次，连续3周。结果：MCC950治疗导致唾液分泌显著减少，并加剧了下颌下腺的白细胞浸润。此外，还伴随着T细胞和B细胞数量增加、Th1反应增强以及下颌下腺中水通道蛋白5表达减少。[6]
存储条件	store at low temperature \| Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
溶解度	10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (8.16 mM), Sonication is recommended. DMSO : 83.33 mg/mL (206.02 mM), Sonication is recommended.
关键字	NOD-like Receptor (NLR) \| NLRP3 \| MCC-950 \| MCC950 \| MCC 950 \| Inhibitor \| inhibit \| CRID-3 \| CRID3 \| CRID 3 \| CP456773 \| CP 456773
相关产品	Bergenin \| Trimethylamine N-oxide \| NLRP3-IN-2 \| β-Aminoarteether \| Imperatorin \| MCC950 sodium \| Articaine hydrochloride \| Stavudine \| Ascorbyl palmitate \| Muscone \| ADS032 \| Troxerutin
相关库	抑制剂库 \| 抗乳腺癌化合物库 \| 经典已知活性库 \| 抗癌化合物库 \| 已知活性化合物库 \| 抗阿尔茨海默症化合物库 \| 抗纤维化化合物库 \| 抗衰老化合物库 \| NO PAINS 化合物库 \| 免疫/炎症分子化合物库 \| NF-κB 通路分子库 \| 抗前列腺癌化合物库

CP-456773|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(13年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务